Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 42

1.

Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.

Martinez Chanza N, Xie W, Issa M, Dzimitrowicz H, Tripathi A, Beuselinck B, Lam E, Zakharia Y, Mckay R, Shah S, Mortazavi A, R Harrison M, Sideris S, Kaymakcalan MD, Abou Alaiwi S, Nassar AH, Nuzzo PV, Hamid A, K Choueiri T, C Harshman L.

J Immunother Cancer. 2020 Mar;8(1). pii: e000538. doi: 10.1136/jitc-2020-000538.

2.

PARP Inhibitors in Prostate and Urothelial Cancers.

Garje R, Vaddepally RK, Zakharia Y.

Front Oncol. 2020 Feb 7;10:114. doi: 10.3389/fonc.2020.00114. eCollection 2020. Review.

3.

Phase Ib/II Clinical Trial of Pembrolizumab With Bevacizumab for Metastatic Renal Cell Carcinoma: BTCRC-GU14-003.

Dudek AZ, Liu LC, Gupta S, Logan TF, Singer EA, Joshi M, Zakharia YN, Lang JM, Schwarz JK, Al-Janadi A, Alva AS.

J Clin Oncol. 2020 Feb 25:JCO1902394. doi: 10.1200/JCO.19.02394. [Epub ahead of print]

PMID:
32097091
4.

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N.

Oncologist. 2020 Feb;25(2):121-e213. doi: 10.1634/theoncologist.2019-0599. Epub 2019 Sep 6.

5.

Histologic Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.

Miller NJ, Khaki AR, Diamantopoulos LN, Bilen MA, Santos V, Agarwal N, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Velho PI, Hahn N, Liu S, Buznego LA, Duran I, Moses M, Jain J, Murgic J, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Lyman GH, Grivas P.

J Urol. 2020 Jan 23:101097JU0000000000000761. doi: 10.1097/JU.0000000000000761. [Epub ahead of print]

PMID:
31971495
6.

Utilization and Outcomes of Surgical Castration in Comparison to Medical Castration in Metastatic Prostate Cancer.

Garje R, Chennamadhavuni A, Mott SL, Chambers IM, Gellhaus P, Zakharia Y, Brown JA.

Clin Genitourin Cancer. 2019 Sep 26. pii: S1558-7673(19)30289-7. doi: 10.1016/j.clgc.2019.09.020. [Epub ahead of print]

7.

The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma.

Garje R, An J, Greco A, Vaddepally RK, Zakharia Y.

Cancers (Basel). 2020 Jan 7;12(1). pii: E143. doi: 10.3390/cancers12010143. Review.

8.

Impact of performance status on treatment outcomes: A real-world study of advanced urothelial cancer treated with immune checkpoint inhibitors.

Khaki AR, Li A, Diamantopoulos LN, Bilen MA, Santos V, Esther J, Morales-Barrera R, Devitt M, Nelson A, Hoimes CJ, Shreck E, Assi H, Gartrell BA, Sankin A, Rodriguez-Vida A, Lythgoe M, Pinato DJ, Drakaki A, Joshi M, Isaacsson Velho P, Hahn N, Liu S, Alonso Buznego L, Duran I, Moses M, Jain J, Murgic J, Baratam P, Barata P, Tripathi A, Zakharia Y, Galsky MD, Sonpavde G, Yu EY, Shankaran V, Lyman GH, Grivas P.

Cancer. 2020 Mar 15;126(6):1208-1216. doi: 10.1002/cncr.32645. Epub 2019 Dec 12.

PMID:
31829450
9.

Efficacy and Adverse Events in Metastatic Melanoma Patients Treated with Combination BRAF Plus MEK Inhibitors Versus BRAF Inhibitors: A Systematic Review.

Greco A, Safi D, Swami U, Ginader T, Milhem M, Zakharia Y.

Cancers (Basel). 2019 Dec 5;11(12). pii: E1950. doi: 10.3390/cancers11121950. Review.

10.

Quantitative test-retest measurement of 68Ga-PSMA-HBED-CC (PSMA-11) in tumor and normal tissue.

Pollard J, Raman C, Zakharia Y, Tracy CR, Nepple KG, Ginader T, Breheny P, Sunderland J.

J Nucl Med. 2019 Dec 5. pii: jnumed.119.236083. doi: 10.2967/jnumed.119.236083. [Epub ahead of print]

PMID:
31806776
11.

A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma.

Hahn AW, Drake C, Denmeade SR, Zakharia Y, Maughan BL, Kennedy E, Link C Jr, Vahanian N, Hammers H, Agarwal N.

Oncologist. 2019 Sep 6. pii: theoncologist.2019-0599. doi: 10.1634/theoncologist.2019-0599. [Epub ahead of print]

12.

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events.

Swami U, Monga V, Bossler AD, Zakharia Y, Milhem M.

J Oncol. 2019 Jul 25;2019:1856594. doi: 10.1155/2019/1856594. eCollection 2019.

13.

Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.

Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, Fleming M, Rezazadeh A, Mellado B, Varlamov S, Joshi M, Duran I, Tagawa ST, Zakharia Y, Zhong B, Stuyckens K, Santiago-Walker A, De Porre P, O'Hagan A, Avadhani A, Siefker-Radtke AO; BLC2001 Study Group.

N Engl J Med. 2019 Jul 25;381(4):338-348. doi: 10.1056/NEJMoa1817323.

PMID:
31340094
14.

Ipilimumab-induced hypophysitis, a single academic center experience.

Snyders T, Chakos D, Swami U, Latour E, Chen Y, Fleseriu M, Milhem M, Zakharia Y, Zahr R.

Pituitary. 2019 Oct;22(5):488-496. doi: 10.1007/s11102-019-00978-4.

PMID:
31327112
15.

The clinical characteristics of melanoma with BRAF V600R mutation: a case series study.

Malkhasyan KA, Rooney SL, Snow AN, Swick BL, Milhem MM, Zakharia Y.

Melanoma Res. 2020 Feb;30(1):107-112. doi: 10.1097/CMR.0000000000000630.

PMID:
31305324
16.

Correction to: Immunotherapy Advances in Urothelial Carcinoma.

Jain RK, Snyders T, Nandagopal L, Garje R, Zakharia Y, Gupta S.

Curr Treat Options Oncol. 2019 May 23;20(7):53. doi: 10.1007/s11864-019-0660-3.

PMID:
31119396
17.

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma.

Swami U, Swick B, Zakharia Y, Milhem M.

Case Rep Oncol Med. 2019 Mar 7;2019:4683531. doi: 10.1155/2019/4683531. eCollection 2019.

18.

Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.

Swami U, Monga V, Freesmeier M, Zhang W, Bossler AD, Zakharia Y, Milhem M.

Melanoma Res. 2019 Dec;29(6):643-647. doi: 10.1097/CMR.0000000000000592.

PMID:
30829928
19.

Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.

Martínez Chanzá N, Xie W, Asim Bilen M, Dzimitrowicz H, Burkart J, Geynisman DM, Balakrishnan A, Bowman IA, Jain R, Stadler W, Zakharia Y, Narayan V, Beuselinck B, McKay RR, Tripathi A, Pachynski R, Hahn AW, Hsu J, Shah SA, Lam ET, Rose TL, Mega AE, Vogelzang N, Harrison MR, Mortazavi A, Plimack ER, Vaishampayan U, Hammers H, George S, Haas N, Agarwal N, Pal SK, Srinivas S, Carneiro BA, Heng DYC, Bosse D, Choueiri TK, Harshman LC.

Lancet Oncol. 2019 Apr;20(4):581-590. doi: 10.1016/S1470-2045(18)30907-0. Epub 2019 Feb 28.

20.

Advanced stage melanoma therapies: Detailing the present and exploring the future.

Luther C, Swami U, Zhang J, Milhem M, Zakharia Y.

Crit Rev Oncol Hematol. 2019 Jan;133:99-111. doi: 10.1016/j.critrevonc.2018.11.002. Epub 2018 Nov 15. Review.

PMID:
30661664

Supplemental Content

Loading ...
Support Center